StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Ruchit Jain, Motilal Oswal

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byRuchit Jain, Motilal OswalHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via NDTV Profit

Entry₹1,217.6Inferred
Target₹1,270
Total upside +4.30% (call closed)
Stop loss₹1,180-3.09% risk
Exit₹1,18030 Sept 2026, 10:00 am
Stop-loss hit-3.09%
Follow Ruchit Jain for new calls(26% target hit, 99 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 3 active Swing calls on ZYDUSLIFESee 161 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
6 supporting2 neutral0 opposing
Supports the BUY call (6)

The USFDA concluded a cGMP inspection at the company's SEZ II manufacturing plant in Ahmedabad with only one observation and no data integrity issues.

BSE · Company Update·28 Sept · yesterday

(opens in new tab)

4 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·29 Sept · yesterday

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · 3d ago

(opens in new tab)

The USFDA inspection of Zydus Lifesciences' USA office for pharmacovigilance and post-marketing systems concluded with no observations.

BSE · Company Update·26 Sept · 3d ago

(opens in new tab)

Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future

NewsCnbc-Tv18·18 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · today

(opens in new tab)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 5d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.